Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ACHILLES THERAPEUTICS PLC

(ACHL)
  Report
Delayed Nasdaq  -  03:59:54 2023-02-06 pm EST
1.260 USD   +5.00%
01/06Achilles Therapeutics : Corporate Presentation – January 2023
PU
2022China Reopening Prospects Lend Some Support to European Equities But Uncertain Outlook Weighs
MT
2022Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Achilles Therapeutics Granted US Patent on Immunotherapy Targeting Clonal Neoantigens Identified Using Proprietary Method

11/22/2022 | 10:42am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ACHILLES CORPORATION 0.40% 1247 Delayed Quote.0.00%
ACHILLES THERAPEUTICS PLC 5.00% 1.26 Delayed Quote.40.00%
All news about ACHILLES THERAPEUTICS PLC
01/06Achilles Therapeutics : Corporate Presentation – January 2023
PU
2022China Reopening Prospects Lend Some Support to European Equities But Uncertain Outlook ..
MT
2022Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GL
2022Achilles Therapeutics plc(NasdaqGS:ACHL) dropped from..
CI
2022Oppenheimer Downgrades Achilles Therapeutics to Perform From Outperform on Lack of Clea..
MT
2022Piper Sandler Cuts Price Target on Achilles Therapeutics to $8 From $10, Keeps Overweig..
MT
2022Chardan Cuts Price Target on Achilles Therapeutics to $17 From $20, Affirms Buy Rating
MT
2022Syncona Portfolio Shares Inch Up on Portfolio Company's Cancer Treatment Update
MT
2022Syncona investee Achilles continues to progress cancer trials
AN
2022Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reac..
AQ
More news
Analyst Recommendations on ACHILLES THERAPEUTICS PLC
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -64,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,75x
Yield 2022 -
Capitalization 51,6 M 51,6 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 247
Free-Float 95,1%
Chart ACHILLES THERAPEUTICS PLC
Duration : Period :
Achilles Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACHILLES THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,26 $
Average target price 11,00 $
Spread / Average Target 773%
EPS Revisions
Managers and Directors
Iraj Ali Chief Executive Officer & Director
Robert Coutts Chief Financial Officer
Edwin Moses Chairman
Karl Peggs Chief Medical Officer
Sergio Quezada Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ACHILLES THERAPEUTICS PLC40.00%52
MODERNA, INC.-3.55%66 559
LONZA GROUP AG21.92%44 368
IQVIA HOLDINGS INC.15.76%44 054
ALNYLAM PHARMACEUTICALS, INC.-1.80%28 711
SEAGEN INC.5.83%25 622